Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cellectar Biosciences, Inc. - Common Stock (NQ:CLRB)

5.610 -0.170 (-2.94%)
Streaming Delayed Price Updated: 12:44 PM EDT, Sep 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 87,690
Open 5.690
Bid (Size) 5.550 (1)
Ask (Size) 5.670 (1)
Prev. Close 5.780
Today's Range 5.500 - 5.700
52wk Range 4.110 - 67.50
Shares Outstanding 1,812,040
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)
Intends to Initiate Phase 1b Clinical Trial in TNBC at Mayo Clinic in Fourth Quarter 2025 
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors 
From Cellectar Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
-42.4%
-42.4%
1 Month
+19.4%
+19.4%
3 Month
-29.3%
-29.3%
6 Month
-48.6%
-48.6%
1 Year
-90.7%
-90.7%

More News

Read More
Earnings Scheduled For August 14, 2025
Via Benzinga
A Peek at Cellectar Biosciences's Future Earnings
Via Benzinga
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Cuts Q2 Losses and Expenses
Via The Motley Fool
Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Which stocks are moving on Tuesday?
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Which stocks are experiencing notable movement on Tuesday?
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
From Cellectar Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Top movers in Wednesday's after hours session
Via Chartmill
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
From Cellectar Biosciences, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Cellectar Biosciences, Inc. - Common Stock publicly traded?
Yes, Cellectar Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Cellectar Biosciences, Inc. - Common Stock trade on?
Cellectar Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cellectar Biosciences, Inc. - Common Stock?
The ticker symbol for Cellectar Biosciences, Inc. - Common Stock is CLRB on the Nasdaq Stock Market
What is the current price of Cellectar Biosciences, Inc. - Common Stock?
The current price of Cellectar Biosciences, Inc. - Common Stock is 5.610
When was Cellectar Biosciences, Inc. - Common Stock last traded?
The last trade of Cellectar Biosciences, Inc. - Common Stock was at 09/25/25 12:44 PM ET
What is the market capitalization of Cellectar Biosciences, Inc. - Common Stock?
The market capitalization of Cellectar Biosciences, Inc. - Common Stock is 10.17M
How many shares of Cellectar Biosciences, Inc. - Common Stock are outstanding?
Cellectar Biosciences, Inc. - Common Stock has 10M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.